 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEBI | |
| ChEMBL | |
| ECHA InfoCard | 100.150.853 |
| Chemical and physical data | |
| Formula | C15H12ClF3N4O |
| Molar mass | 356.73 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
BAY 73-6691 is a drug developed byBayer for the treatment ofAlzheimer's disease. It was the first compound developed that acts as aphosphodiesterase inhibitor selective for thePDE9A subtype. The PDE9A enzyme is expressed primarily in the brain, with high concentrations in thecerebellum,neocortex,striatum, andhippocampus, and acts to limit thecGMP-mediatedsignal transduction which occurs followingglutamate binding toNMDA receptors. Consequently, selective PDE9A inhibitors were predicted to prolong intracellular responses to glutamate and enhance glutamate signalling, and since this process is known to be involved in learning and memory, PDE9A inhibitors should have anootropic effect and may be useful in the treatment of Alzheimer's.[1]
Animal studies have confirmed these expectations, and BAY 73-6691 has been shown to improve learning and memory in rats.[2] As the first selective PDE9A inhibitor to be developed, it is also widely used in research into the function of this enzyme subtype. However pre-clinical research is at an early stage and it is not yet known whether BAY 73-6691 will prove suitable to progress to human trials, or if it will remain merely a laboratory research tool.